Opportunity Knocks in AML
58:31
Mastering the Integration of Immunotherapy in Resectable NSCLC
1:30:46
Precision Treatment Planning With Molecularly Targeted Therapies in HER2+ GI Cancers
7:09
Under-the-radar biotech bets
16:34
Excess deaths in young adults
1:07:00
Strengthening the Immunotherapy Paradigm in Advanced SCAC
53:25
Targeting Higher Standards in Resectable NSCLC
47:14
Charting a New Course in Limited-Stage SCLC Amid an Immunotherapy Sea Change
1:34:23